Literature DB >> 25416199

Antiphospholipid syndrome and other autoimmune diseases associated with chronic intervillositis.

Aurélie Revaux1, Arsène Mekinian, Pascale Nicaise, Martine Bucourt, Françoise Cornelis, Eric Lachassinne, Sylvie Chollet-Martin, Olivier Fain, Lionel Carbillon.   

Abstract

OBJECTIVES: Chronic intervillositis of unknown etiology (CIUE) is characterized by an intervillous infiltrate of mononuclear cells and a high recurrence rate of adverse obstetrical outcomes. The aim was to describe obstetrical history in patients with at least one event characterized by CIUE, and the possible impact of systematic investigation of an underlying autoimmune disease on the obstetrical outcome of subsequent pregnancies.
METHODS: We retrospectively reviewed all pregnancies in patients having experienced at least one adverse obstetric outcome associated with chronic intervillositis of unknown etiology diagnosed by placental histological analysis between 2004 and 2011 in our university hospital. For each patient, data pertaining to obstetrical history, treatments during pregnancies, the results of systematic investigation of an underlying autoimmune disease, and treatments as well as obstetrical outcome in subsequent pregnancies, were collected.
RESULTS: Twelve patients with 38 pregnancies were included [median age 30 (22; 40 years)]. Autoimmune disease or autoimmune antibodies (AID group) were found in 7/12 patients: primary antiphospholipid syndrome (APS) (n = 4), Sjögren's syndrome (n = 1), pernicious anemia (n = 1) and celiac disease (n = 1). When comparing pregnancies of patients with and without AID, there was no difference with regard to the type of obstetrical events or live-born babies, in spite of appropriate treatment. Corticosteroids (prednisone 10 mg/day) were used in only 2 cases with AID (Sjögren's syndrome and APS; n = 1 each), and these 2 pregnancies resulted in live-born babies.
CONCLUSION: This study shows that the immunological assessment in patients with CIUE raises the possibility of a specific severity when AID or obstetrical APS is associated with CIUE, since conventional treatment did not improve obstetrical outcome in these patients as compared to those without autoimmune diseases. The benefit of immunosuppressant agents in this subset of patients needs further evaluation.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25416199     DOI: 10.1007/s00404-014-3536-6

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  3 in total

1.  Hypertensive disease, preterm birth, fetal growth restriction and chronic inflammatory disorders of the placenta: experiences in a single institution with a standardized protocol of investigation.

Authors:  Henning Feist; Simin Bajwa; Ulrich Pecks
Journal:  Arch Gynecol Obstet       Date:  2021-10-24       Impact factor: 2.493

Review 2.  Chronic Inflammatory Placental Disorders Associated With Recurrent Adverse Pregnancy Outcome.

Authors:  Emily F Cornish; Thomas McDonnell; David J Williams
Journal:  Front Immunol       Date:  2022-04-22       Impact factor: 8.786

3.  Immunomodulatory Therapy Reduces the Severity of Placental Lesions in Chronic Histiocytic Intervillositis.

Authors:  Chloe A Brady; Charlotte Williams; Gauri Batra; Elaine Church; Clare L Tower; Ian P Crocker; Alexander E P Heazell
Journal:  Front Med (Lausanne)       Date:  2021-10-18
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.